In agreement with literature, targeting the STAT3 pathway is an upcoming therapeutic approach in the treatment of a rising number of inflammatory or proliferative diseases, like myelofibrosis, myeloproliferative disorders, rheumatoid arthritis and colitis ulcerosa also has a modulating effect on vascular cell function. This evidence concerns the gene STAT3 and rheumatoid arthritis.